BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 2585020)

  • 21. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
    Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A
    N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma.
    Vose JM; Armitage JO; Weisenburger DD; Bierman PJ; Sorensen S; Hutchins M; Moravec DF; Howe D; Dowling MD; Mailliard J
    J Clin Oncol; 1988 Dec; 6(12):1838-44. PubMed ID: 2462026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunophenotype, histopathology and clinical stage: their predictive value in the prognosis of non-Hodgkin's lymphomas.
    Mtasiwa DM; Imamura N; Inada T; Takimoto Y; Okada K; Nanba K; Asaoku H; Kuramoto A
    Hiroshima J Med Sci; 1990 Dec; 39(4):95-102. PubMed ID: 2086567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group.
    Cooper IA; Wolf MM; Robertson TI; Fox RM; Matthews JP; Stone JM; Ding JC; Dart G; Matthews J; Firkin FC
    J Clin Oncol; 1994 Apr; 12(4):769-78. PubMed ID: 7512131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
    Salzburg J; Burkhardt B; Zimmermann M; Wachowski O; Woessmann W; Oschlies I; Klapper W; Wacker HH; Ludwig WD; Niggli F; Mann G; Gadner H; Riehm H; Schrappe M; Reiter A
    J Clin Oncol; 2007 Sep; 25(25):3915-22. PubMed ID: 17761975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparing CHOP, CHOP+HD-MTX,and BFM-90 regimens in the survival rate of children and adolescents with B cell non-Hodgkin's lymphoma].
    Sun XF; Su YS; Liu DG; Jiang WQ; He YJ; Lin TY; Huang HQ; Zhang L; Xia ZJ; Li YH; Zhou ZM; Chen XQ; Xia Y; Zhen ZJ; Guan ZZ
    Ai Zheng; 2004 Aug; 23(8):933-8. PubMed ID: 15301718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma.
    Rossi G; Donisi A; Casari S; Re A; Cadeo G; Carosi G
    Cancer; 1999 Dec; 86(11):2391-7. PubMed ID: 10590382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
    De Lena M; Ditonno P; Lorusso V; Brandi M; Timurian A; Marzullo F; Ventrella V; Pellecchia A
    J Clin Oncol; 1995 Apr; 13(4):953-60. PubMed ID: 7535844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, prednisolone (VEPA) in non-Hodgkin's lymphoma, with special reference to correlation of surface phenotype with response and survival].
    Chubachi A; Miura AB; Yamaguchi A; Nishimura S
    Gan To Kagaku Ryoho; 1988 Jul; 15(7):2057-63. PubMed ID: 3293535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study.
    Freedman AS; Takvorian T; Neuberg D; Mauch P; Rabinowe SN; Anderson KC; Soiffer RJ; Spector N; Grossbard M; Robertson MJ
    J Clin Oncol; 1993 May; 11(5):931-6. PubMed ID: 8487057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of monoclonal antibody phenotyping and cellular DNA content in non-Hodgkin's lymphoma. The Southeastern Cancer Study Group experience.
    Wain SL; Braylan RC; Borowitz MJ
    Cancer; 1987 Nov; 60(10):2403-11. PubMed ID: 3499212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low grade malignant non-Hodgkin's lymphomas and peripheral pleomorphic T-cell lymphomas in childhood--a BFM study group report.
    Bucsky P; Feller AC; Reiter A; Beck J; Bertram U; Eschenbach C; Gerein V; Lakomek M; Stollmann B; Tausch W
    Klin Padiatr; 1990; 202(4):258-61. PubMed ID: 2203939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B cell non-Hodgkin's lymphoma: experience from a tertiary care cancer center.
    Prakash G; Sharma A; Raina V; Kumar L; Sharma MC; Mohanti BK
    Ann Hematol; 2012 Oct; 91(10):1603-11. PubMed ID: 22584851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
    Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
    Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy.
    Waits TM; Greco FA; Greer JP; Johnson DH; Wolff SN; Stein RS; McMaster ML; Hainsworth JD
    J Clin Oncol; 1993 May; 11(5):943-9. PubMed ID: 7683712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation between histology and immunophenotype in a series of 322 cases of non-Hodgkin's lymphoma.
    Smith JL; Jones DB; Bell AJ; Wright DH
    Hematol Oncol; 1989; 7(1):37-48. PubMed ID: 2642457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elderly patients with non-Hodgkin's lymphoma: population-based results in The Netherlands.
    Maartense E; Hermans J; Kluin-Nelemans JC; Kluin PM; Van Deijk WA; Snijder S; Wijermans PW; Noordijk EM
    Ann Oncol; 1998 Nov; 9(11):1219-27. PubMed ID: 9862053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of immunophenotype in aggressive non-Hodgkin's lymphoma.
    Tsartsidze E; Betaneli M
    Georgian Med News; 2006 May; (134):107-9. PubMed ID: 16783081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of the adhesion molecule ICAM-1 in non-Hodgkin's lymphoma: relationship with tumor dissemination and prognostic importance.
    Terol MJ; López-Guillermo A; Bosch F; Villamor N; Cid MC; Rozman C; Campo E; Montserrat E
    J Clin Oncol; 1998 Jan; 16(1):35-40. PubMed ID: 9440720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
    Huang HQ; Lin XB; Pan ZH; Bu Q; Gao Y; Wang BF; Cai QQ; Xia ZJ; Xu RH; Jiang WQ; Guan ZZ
    Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):391-5. PubMed ID: 17892140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.